Respicardia®, Inc., a developer of implantable therapies to improve respiratory and cardiovascular health, announced that it has been awarded the U.S. Healthcare Product of the Year by Acquisition International (AI) for the remede® System, the first and only implantable device for the treatment of central sleep apnea. AI recognizes leaders in their fields for achievement and innovation.
"We are pleased to receive this award from Acquisition International and are grateful that the industry has recognized the value of the remede System," said Tim Hauch, CFO of Respicardia. "This award acknowledges our efforts to develop a meaningful therapy and provide an innovative solution for cardiovascular disease patients with central sleep apnea."
The remede System has received CE mark in Europe and is currently being evaluated in an FDA approved pivotal trial at 25 centers in the U.S., with additional centers in Europe. Positive results from the pilot study evaluating the effects of the remede System were presented at the 2013 European Society of Cardiology (ESC) in Amsterdam, and in Late Breaking Clinical Trial session at the Heart Failure Society of America meeting held in Orlando, Florida last month.
Exploring AI's role in transforming healthcare diagnosis and treatment